GlassScriptPhysician profile
Oltjon Albajrami
NPI 1336371566
$2,669.01
in general payments reported to CMS, 2019-2025
26 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.04 · 2021: $218 · 2022: $528 · 2023: $621 · 2024: $661 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895 · Education: $9.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.57 |
| Education | $9.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $423.06 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $273.65 | 2021-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $203.15 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $197.18 | 2021-2024 | |
| Lilly USA, LLC | $169.75 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $146.35 | 2024-2025 | |
| Amgen INC. | $136.86 | 2023-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $125.65 | 2022-2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $121.05 | 2022-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $102.66 | 2022-2025 | Tarpeyo |
| Ascendis Pharma Endocrinology INC | $82.98 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.15 | 2022-2025 | Jardiance |
| Daiichi Sankyo INC. | $76.58 | 2021-2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $72.51 | 2023-2025 | Ultomiris |
| Horizon Therapeutics Plc | $67.42 | 2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.15 | 2024-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $58.20 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $51.96 | 2021-2023 | Velphoro |
| Ani Pharmaceuticals, INC. | $48.98 | 2022-2025 | Purified Cortrophin Gel |
| Cormedix INC. | $48.20 | 2024 | Defencath |
| Vifor Pharma, INC. | $47.09 | 2023-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $22.13 | 2021 | |
| Nxstage Medical, INC. | $19.04 | 2019 | |
| Baxter Healthcare | $15.91 | 2022 | |
| Akebia Therapeutics INC | $15.35 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oltjon Albajrami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.